Intratracheal and oral administration of SM-276001: A selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV

(2011) J. F. Bergmann et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection

(2011) Thien-Duc Tran et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway

(2011) J. Z. Oh et al.   BLOOD

Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy

(2011) R. Waitz et al.   CANCER RESEARCH

Toll-like Receptor 7–triggered Immune Response in the Lung Mediates Acute and Long-Lasting Suppression of Experimental Asthma

(2010) Charoula Xirakia et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

(2010) D. Rajagopal et al.   BLOOD

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8

(2010) D. Wang et al.   MOLECULAR CANCER THERAPEUTICS

The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis

(2010) P. Vandenabeele et al.   Science Signaling

Treatment of metastatic renal cell carcinoma

(2009) David J. Reeves et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Toll-like receptors - sentries in the B-cell response

(2009) Isabelle Bekeredjian-Ding et al.   IMMUNOLOGY

Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy

(2009) S. A. Broomfield et al.   JOURNAL OF IMMUNOLOGY

CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity

(2009) Sara M. Mangsbo et al.   JOURNAL OF IMMUNOTHERAPY

Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists

(2009) Svetlana Hamm et al.   Journal of Immunotoxicology

An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models

(2008) S Dharmapuri et al.   CANCER GENE THERAPY

TLR7 and TLR8 as targets in cancer therapy

(2008) M P Schön et al.   ONCOGENE

The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy

(2008) E. L. J. M. Smits et al.   ONCOLOGIST